Want to see GNLX full AI Analyst Report?
Top Page
Genelux Corp.
(NASDAQ:GNLX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.00
▼(-26.47% Downside)
Action:Reiterated
Date:10/22/26
The score is primarily held down by very weak financial performance—near-zero revenue, large ongoing losses, and heavy cash burn implying continued funding needs. Technicals also point to a prevailing downtrend (below major moving averages with negative MACD). Valuation provides limited support given the negative P/E and no dividend yield data.
Positive Factors
Proprietary oncology platform
Olvi-Vec provides Genelux with a proprietary virus-based immunotherapy platform focused on selectively targeting tumors and stimulating anti-tumor immune responses. Clinical validation remains necessary, but the platform creates a defined technological foundation for future development.
Negative Factors
Minimal commercial revenue
Near-zero revenue shows that Genelux has not yet established a commercial operating model and remains dependent on successful clinical and regulatory execution. Until a candidate is approved or partnered, the business lacks recurring product revenue to support ongoing activities.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary oncology platform
Olvi-Vec provides Genelux with a proprietary virus-based immunotherapy platform focused on selectively targeting tumors and stimulating anti-tumor immune responses. Clinical validation remains necessary, but the platform creates a defined technological foundation for future development.
Read all positive factors
Genelux Corp. (GNLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.42M
Dividend YieldN/A
Average Volume (3M)312.04K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue GrowthN/A
EPS Growth-1.31%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.89
Shares Outstanding45,245,335
10 Day Avg. Volume464,949
30 Day Avg. Volume312,040
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue14.88K
Enterprise Value/Gross Profit-844.52
Enterprise Value/Ebitda-3.49
Forecast
1Y Price Target
$20.33Price Target Upside647.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Genelux Corp. Business Overview & Revenue Model
Company Description
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi...
How the Company Makes Money
As a clinical-stage biotechnology company, Genelux does not have widely disclosed, established product sales as a primary revenue source; commercial revenue from approved therapeutics is null. The company’s funding has historically been driven pri...
Genelux Corp. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.00K | 8.00K | 8.00K | 170.00K | 11.07M | 0.00 |
| Gross Profit | -141.00K | -566.00K | -895.00K | -848.00K | 10.10M | -895.00K |
| EBITDA | -34.14M | -31.57M | -28.97M | -26.46M | -1.73M | -13.67M |
| Net Income | -33.79M | -32.15M | -29.87M | -28.30M | -5.21M | -17.80M |
Balance Sheet | ||||||
| Total Assets | 26.20M | 19.03M | 34.72M | 27.89M | 5.53M | 8.13M |
| Cash, Cash Equivalents and Short-Term Investments | 18.67M | 14.60M | 30.89M | 23.19M | 397.00K | 4.50M |
| Total Debt | 2.42M | 1.69M | 1.87M | 2.52M | 26.35M | 25.31M |
| Total Liabilities | 10.09M | 7.48M | 8.44M | 8.42M | 41.31M | 41.24M |
| Stockholders Equity | 16.11M | 11.54M | 26.27M | 19.47M | -35.78M | -33.11M |
Cash Flow | ||||||
| Free Cash Flow | -28.68M | -26.37M | -21.61M | -21.30M | -3.62M | -6.58M |
| Operating Cash Flow | -25.28M | -25.27M | -21.23M | -20.27M | -3.57M | -6.58M |
| Investing Cash Flow | 8.71M | 12.14M | -8.13M | -14.72M | -49.00K | 0.00 |
| Financing Cash Flow | 19.20M | 9.89M | 28.51M | 44.02M | -478.00K | -270.00K |
Genelux Corp. Technical Analysis
Negative
2.72
Price Trends
2.51
Negative
2.70
Negative
2.71
Negative
Market Momentum
-0.13
Positive
28.54
Positive
7.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNLX, the sentiment is Negative. The current price of 2.72 is above the 20-day moving average (MA) of 2.40, above the 50-day MA of 2.51, and above the 200-day MA of 2.71, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 28.54 is Positive, neither overbought nor oversold. The STOCH value of 7.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNLX.
Genelux Corp. Risk Analysis
Genelux Corp. disclosed 88 risk factors in its most recent earnings report. Genelux Corp. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Genelux Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $246.23M | -1.96 | -65.08% | ― | -23.36% | 27.52% | |
48 Neutral | $90.90M | -0.40 | -68.99% | ― | 196.02% | 98.71% | |
44 Neutral | $156.05M | -0.99 | -181.73% | ― | -64.32% | 25.83% | |
44 Neutral | $77.17M | -0.62 | -87.05% | ― | ― | -29.66% | |
43 Neutral | $86.42M | -2.15 | -195.42% | ― | ― | -1.31% |
* Healthcare Sector Average
GNLX
Genelux Corp.
1.91
-5.39
-73.84%
CHRS
Coherus Biosciences
1.01
-0.59
-36.88%
FATE
Fate Therapeutics
2.06
0.51
32.58%
TNXP
Tonix Pharma
5.30
-15.05
-73.96%
CRBP
Corbus Pharmaceuticals
3.99
-13.02
-76.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.